Update Breast Cancer 2024 Part 2-Patients with Early Stage Breast Cancer

Wolfgang Janni; Hans Christian Kolberg; Andreas D. Hartkopf; Tanja N. Fehm; Manfred Welslau; Volkmar Müller; Florian Schütz; Peter A. Fasching; Christian Jackisch; Frederik Marme; Manuel Hörner; Katharina Keller; Chloë Goossens; Erik Belleville; Michael Untch; Marc Thill; Hans Tesch; Nina Ditsch; Michael P. Lux; Maggie Banys-Paluchowski; Achim Wöckel; Nadia Harbeck; Elmar Stickeler; Rupert Bartsch; Bahriye Aktas; Andreas Schneeweiss; Johannes Ettl; Florin Andrei Taran; Diana Lüftner; Rachel Würstlein; Julia C. Radosa

doi:10.1055/a-2533-2783

Update Breast Cancer 2024 Part 2-Patients with Early Stage Breast Cancer

Titel in Übersetzung: Update Mammakarzinom 2024 Teil 2 – Patientinnen mit Frühstadien des Mammakarzinoms

Wolfgang Janni, Hans Christian Kolberg, Andreas D. Hartkopf, Tanja N. Fehm, Manfred Welslau, Volkmar Müller, Florian Schütz, Peter A. Fasching^*, Christian Jackisch, Frederik Marme, Manuel Hörner, Katharina Keller, Chloë Goossens, Erik Belleville, Michael Untch, Marc Thill, Hans Tesch, Nina Ditsch, Michael P. Lux, Maggie Banys-PaluchowskiAchim Wöckel, Nadia Harbeck, Elmar Stickeler, Rupert Bartsch, Bahriye Aktas, Andreas Schneeweiss, Johannes Ettl, Florin Andrei Taran, Diana Lüftner, Rachel Würstlein, Julia C. Radosa

^*Korrespondierende/r Autor/-in für diese Arbeit

3 Zitate (Scopus)

Abstract

This review summarizes the latest developments for the treatment of patients with early-stage breast cancer. Most of the clinically relevant changes were the result of using immune checkpoint inhibitors to treat patients with triple-negative breast cancer (TNBC) and CDK4/6 inhibitors to treat patients with hormone receptor-positive, HER2-negative (HRpos/HER2neg) tumors and a high risk of recurrence. Recent studies are presenting more and more data with long follow-up times and integrating translational analyses to evaluate new biomarkers such as circulating tumor DNA (ctDNA). This review article summarizes the latest developments published in recent months and puts the findings in context.

Titel in Übersetzung	Update Mammakarzinom 2024 Teil 2 – Patientinnen mit Frühstadien des Mammakarzinoms
Originalsprache	Englisch
Zeitschrift	Geburtshilfe und Frauenheilkunde
Jahrgang	85
Ausgabenummer	5
Seiten (von - bis)	493-506
Seitenumfang	14
ISSN	0016-5751
DOIs	https://doi.org/10.1055/a-2533-2783
Publikationsstatus	Veröffentlicht - 15.05.2025

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

Profilbereich: Lübeck Integrated Oncology Network (LION)

DFG-Fachsystematik

2.22-14 Hämatologie, Onkologie
2.22-21 Gynäkologie und Geburtshilfe

Dokumente

10.1055/a-2533-2783

Weitere Links

Zitieren

Janni, W., Kolberg, H. C., Hartkopf, A. D., Fehm, T. N., Welslau, M., Müller, V., Schütz, F., Fasching, P. A., Jackisch, C., Marme, F., Hörner, M., Keller, K., Goossens, C., Belleville, E., Untch, M., Thill, M., Tesch, H., Ditsch, N., Lux, M. P., ... Radosa, J. C. (2025). Update Breast Cancer 2024 Part 2-Patients with Early Stage Breast Cancer. Geburtshilfe und Frauenheilkunde, 85(5), 493-506. https://doi.org/10.1055/a-2533-2783

@article{f814e53fff8e484db90576ad1e0adeb4,

title = "Update Breast Cancer 2024 Part 2-Patients with Early Stage Breast Cancer",

abstract = "This review summarizes the latest developments for the treatment of patients with early-stage breast cancer. Most of the clinically relevant changes were the result of using immune checkpoint inhibitors to treat patients with triple-negative breast cancer (TNBC) and CDK4/6 inhibitors to treat patients with hormone receptor-positive, HER2-negative (HRpos/HER2neg) tumors and a high risk of recurrence. Recent studies are presenting more and more data with long follow-up times and integrating translational analyses to evaluate new biomarkers such as circulating tumor DNA (ctDNA). This review article summarizes the latest developments published in recent months and puts the findings in context.",

author = "Wolfgang Janni and Kolberg, \{Hans Christian\} and Hartkopf, \{Andreas D.\} and Fehm, \{Tanja N.\} and Manfred Welslau and Volkmar M{\"u}ller and Florian Sch{\"u}tz and Fasching, \{Peter A.\} and Christian Jackisch and Frederik Marme and Manuel H{\"o}rner and Katharina Keller and Chlo{\"e} Goossens and Erik Belleville and Michael Untch and Marc Thill and Hans Tesch and Nina Ditsch and Lux, \{Michael P.\} and Maggie Banys-Paluchowski and Achim W{\"o}ckel and Nadia Harbeck and Elmar Stickeler and Rupert Bartsch and Bahriye Aktas and Andreas Schneeweiss and Johannes Ettl and Taran, \{Florin Andrei\} and Diana L{\"u}ftner and Rachel W{\"u}rstlein and Radosa, \{Julia C.\}",

note = "Publisher Copyright: {\textcopyright} 2025. The Author(s). The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).",

year = "2025",

month = may,

day = "15",

doi = "10.1055/a-2533-2783",

language = "English",

volume = "85",

pages = "493--506",

journal = "Geburtshilfe und Frauenheilkunde",

issn = "0016-5751",

publisher = "Georg Thieme Verlag",

number = "5",

}

Janni, W, Kolberg, HC, Hartkopf, AD, Fehm, TN, Welslau, M, Müller, V, Schütz, F, Fasching, PA, Jackisch, C, Marme, F, Hörner, M, Keller, K, Goossens, C, Belleville, E, Untch, M, Thill, M, Tesch, H, Ditsch, N, Lux, MP, Banys-Paluchowski, M, Wöckel, A, Harbeck, N, Stickeler, E, Bartsch, R, Aktas, B, Schneeweiss, A, Ettl, J, Taran, FA, Lüftner, D, Würstlein, R & Radosa, JC 2025, 'Update Breast Cancer 2024 Part 2-Patients with Early Stage Breast Cancer', Geburtshilfe und Frauenheilkunde, Jg. 85, Nr. 5, S. 493-506. https://doi.org/10.1055/a-2533-2783

TY - JOUR

T1 - Update Breast Cancer 2024 Part 2-Patients with Early Stage Breast Cancer

AU - Janni, Wolfgang

AU - Kolberg, Hans Christian

AU - Hartkopf, Andreas D.

AU - Fehm, Tanja N.

AU - Welslau, Manfred

AU - Müller, Volkmar

AU - Schütz, Florian

AU - Fasching, Peter A.

AU - Jackisch, Christian

AU - Marme, Frederik

AU - Hörner, Manuel

AU - Keller, Katharina

AU - Goossens, Chloë

AU - Belleville, Erik

AU - Untch, Michael

AU - Thill, Marc

AU - Tesch, Hans

AU - Ditsch, Nina

AU - Lux, Michael P.

AU - Banys-Paluchowski, Maggie

AU - Wöckel, Achim

AU - Harbeck, Nadia

AU - Stickeler, Elmar

AU - Bartsch, Rupert

AU - Aktas, Bahriye

AU - Schneeweiss, Andreas

AU - Ettl, Johannes

AU - Taran, Florin Andrei

AU - Lüftner, Diana

AU - Würstlein, Rachel

AU - Radosa, Julia C.

N1 - Publisher Copyright: © 2025. The Author(s). The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).

PY - 2025/5/15

Y1 - 2025/5/15

N2 - This review summarizes the latest developments for the treatment of patients with early-stage breast cancer. Most of the clinically relevant changes were the result of using immune checkpoint inhibitors to treat patients with triple-negative breast cancer (TNBC) and CDK4/6 inhibitors to treat patients with hormone receptor-positive, HER2-negative (HRpos/HER2neg) tumors and a high risk of recurrence. Recent studies are presenting more and more data with long follow-up times and integrating translational analyses to evaluate new biomarkers such as circulating tumor DNA (ctDNA). This review article summarizes the latest developments published in recent months and puts the findings in context.

AB - This review summarizes the latest developments for the treatment of patients with early-stage breast cancer. Most of the clinically relevant changes were the result of using immune checkpoint inhibitors to treat patients with triple-negative breast cancer (TNBC) and CDK4/6 inhibitors to treat patients with hormone receptor-positive, HER2-negative (HRpos/HER2neg) tumors and a high risk of recurrence. Recent studies are presenting more and more data with long follow-up times and integrating translational analyses to evaluate new biomarkers such as circulating tumor DNA (ctDNA). This review article summarizes the latest developments published in recent months and puts the findings in context.

UR - https://www.scopus.com/pages/publications/105005591411

UR - https://www.mendeley.com/catalogue/b16fd482-362c-3a26-889d-6df2dc94f3da/

U2 - 10.1055/a-2533-2783

DO - 10.1055/a-2533-2783

M3 - Scientific review articles

C2 - 40386499

AN - SCOPUS:105005591411

SN - 0016-5751

VL - 85

SP - 493

EP - 506

JO - Geburtshilfe und Frauenheilkunde

JF - Geburtshilfe und Frauenheilkunde

IS - 5

ER -

Update Breast Cancer 2024 Part 2-Patients with Early Stage Breast Cancer

Abstract

UN SDGs

Strategische Forschungsbereiche und Zentren

DFG-Fachsystematik

Dokumente

Weitere Links

Fingerprint

Zitieren